venetoclax + zanubrutinib

**venetoclax + zanubrutinib** is a combination of two targeted small molecule therapies, each with distinct mechanisms of action. Venetoclax is a highly selective, orally bioavailable B-cell lymphoma 2 (BCL2) inhibitor that promotes apoptosis of malignant B cells by inhibiting the anti-apoptotic BCL2 protein. Zanubrutinib is a next-generation, highly selective, orally active Bruton tyrosine kinase (BTK) inhibitor, which irreversibly binds BTK and disrupts B-cell receptor signaling, thus blocking B-cell proliferation and survival. This combination has been developed to target two crucial survival pathways in B-cell malignancies and addresses the problem of resistance that often develops with single-agent therapies. Clinical trials, including the SEQUOIA phase 3 trial, have demonstrated robust efficacy, particularly in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), including subpopulations with high-risk features such as TP53 mutation or 17p deletion. Nanoparticle formulations (VZ-DcNP) are also under investigation to provide synchronized and sustained delivery of both agents for improved efficacy and pharmacokinetics[1][2][5][7].

Brand names

no unique brand name for the combination

Other names

VZ-DcNP (for nanoparticle formulation)ZV (abbreviation in clinical trials)